全文获取类型
收费全文 | 1496篇 |
免费 | 132篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 79篇 |
妇产科学 | 10篇 |
基础医学 | 79篇 |
口腔科学 | 8篇 |
临床医学 | 107篇 |
内科学 | 497篇 |
皮肤病学 | 39篇 |
神经病学 | 192篇 |
特种医学 | 13篇 |
外国民族医学 | 1篇 |
外科学 | 98篇 |
综合类 | 108篇 |
预防医学 | 49篇 |
眼科学 | 2篇 |
药学 | 112篇 |
2篇 | |
中国医学 | 82篇 |
肿瘤学 | 176篇 |
出版年
2024年 | 3篇 |
2023年 | 52篇 |
2022年 | 70篇 |
2021年 | 82篇 |
2020年 | 99篇 |
2019年 | 98篇 |
2018年 | 93篇 |
2017年 | 59篇 |
2016年 | 87篇 |
2015年 | 43篇 |
2014年 | 89篇 |
2013年 | 135篇 |
2012年 | 58篇 |
2011年 | 63篇 |
2010年 | 40篇 |
2009年 | 51篇 |
2008年 | 35篇 |
2007年 | 44篇 |
2006年 | 32篇 |
2005年 | 40篇 |
2004年 | 39篇 |
2003年 | 40篇 |
2002年 | 34篇 |
2001年 | 23篇 |
2000年 | 12篇 |
1999年 | 17篇 |
1998年 | 19篇 |
1997年 | 17篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 22篇 |
1993年 | 11篇 |
1992年 | 14篇 |
1991年 | 12篇 |
1990年 | 9篇 |
1989年 | 5篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 5篇 |
排序方式: 共有1656条查询结果,搜索用时 15 毫秒
1.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献2.
3.
Hiroto Kinoshita Hitomi Nishioka Aya Ikeda Kyoko Ikoma Yoichi Sameshima Hidehisa Ohi Mizuki Tatsuno Junka Kouyama Chiaki Kawamoto Tomohiro Mitsui Yuko Tamura Yu Hashimoto Masashi Nishio Tsuyoshi Ogashiwa Yusuke Saigusa Shin Maeda Hideaki Kimura Reiko Kunisaki Kazuhiko Koike 《Journal of gastroenterology and hepatology》2019,34(11):1929-1939
4.
目的 应用Meta分析的方法评价进展期霍奇金病经化疗达完全缓解后巩固放疗的作用。材料和方法 在MEDLINE、CBMdisc数据库检索进展期霍奇金病化疗达完全缓解行巩固性放疗或不行巩固性放疗的前瞻性随机对照研究。对入选研究的总生存、无事件生存优势比进行Meta分析。结果 4项研究入选,以α=0.05为检验水准,巩固性放疗组与对照组(不作巩固性放疗)相比,5年总生存优势比=1.18,P=0.46;5年无事件生存优势比=1.05.P=0.83:巩固性侵犯野放疗组与对照组相比,5年总生存优势比=0.96,P=0.87。结论 进展期霍奇金病经化疗达到完全缓解后,巩固性放疗对总生存及无事件生存均无益处。 相似文献
5.
6.
Prediction of Remission of Acute Posttraumatic Stress Disorder in Motor Vehicle Accident Victims 总被引:1,自引:0,他引:1
Edward B. Blanchard Edward J. Hickling Catherine A. Forneris Ann E. Taylor Todd C. Buckley Warren R. Loos James Jaccard 《Journal of traumatic stress》1997,10(2):215-234
One hundred forty five individuals who sought medical attention as a result of a motor vehicle accident (MVA), and who were initially assessed 1 to 4 months post-MVA, were followed up prospectively for 6 months to determine how many of the 55 with posttraumatic stress disorder (PTSD) and the 43 with sub-syndromal PTSD would remit and what variables would predict remission. Thirty (55%) of those with initial PTSD had remitted at least in part by 6 months while 67% of those with sub-syndromal PTSD had remitted (and 5% had worsened). Four variables, including severity of initial symptoms, degree of initial physical injury, relative degree of physical recovery by 4 months and whether a close family member suffered a trauma during the follow-up interval, combined to classify 6-month clinical status of 84% of those with initial PTSD secondary to MVAs. 相似文献
7.
成人ANLL初治患者61例用HA方案和DA方案治疗的效果相似(包括CR率,中位缓解时间),而HA方案的心脏毒性及并发严重感染率均较DA方案少见和轻微(P<0.01)。成人ANLL140例用VMP或VDP方案治疗的效果相仿,而VMP方案治疗骨髓抑制率及并发严重感染率较少见和轻微(P<0.05)。结果表明,HA或VMP方案对白血病细胞均有明显的杀伤,可以分别替代DA和VDP方案,具有实用价值;HA和H 相似文献
8.
V. Gh. MUSTEATA I. T. CORCIMARU I. A. IACOVLEVA L. Z. MUSTEATA I. S. SUHARSCHII L. T. ANTOCI 《International journal of laboratory hematology》2004,26(6):397-401
The purpose of this comparative study was to evaluate the response of primary splenic low‐grade non‐Hodgkin's lymphomas (NHL) to chemotherapy, splenectomy, and chemotherapy combined with splenectomy in order to elaborate the optimum treatment modality. A total of 104 patients (age range: 15–82 years) with primary low‐grade B‐cell NHL of the spleen were comprised by our study. Stage IV disease was determined in 102 (98.1%) cases. Regarding the treatment modality, splenectomy was performed in 14 patients, early splenectomy and single‐agent chemotherapy in 15, early splenectomy and combined chemotherapy in 19, single‐agent chemotherapy in 23, and combined chemotherapy in 33. In the above‐mentioned order, complete remission rate was following: none, 40.0, 31.6, 21.8, and 18.2%. Partial remissions were achieved in 85.7, 46.7, 57.9, 30.4, and 69.7% of cases, respectively. The median remission duration turned out to be longer (74.5 months) in the group of patients with complete remissions attained by means of splenectomy and combined chemotherapy. Local relapses in the spleen developed in 19 (72.7%) patients treated with combined chemotherapy and in 9 (90.0%), who had undergone single‐agent chemotherapy. The 5‐year overall survival was 54.4% after splenectomy, 39.4% after single‐agent chemotherapy, and 37.1% after combined chemotherapy, being significantly higher (P < 0.05) after splenectomy and single‐agent chemotherapy (67.2%), and splenectomy followed by combined chemotherapy (64.7%). Early splenectomy combined with chemotherapy is the optimum treatment option for primary low‐grade NHL of the spleen because of the superiority in complete remission rate, remission duration, and in overall survival rate. Splenectomy leads to somatic compensation of patients, makes impossible local relapsing in the spleen, prevents continuous dissemination from the primary tumor site, and mostly corrects cytopenias, creating better conditions for chemotherapy. 相似文献
9.
Azra Raza Harvey D. Preisler Ya Qin Li Richard A. Larson Jack Goldberg George Browman John Bennett Hans Grunwald Ralph Vogler Cathi Kukla 《American journal of hematology》1993,42(4):359-366
A pilot study was conducted of the biological characteristics of the leukemia cells of newly diagnosed patients with poor prognosis acute myelogenous leukemia (AML). This study included measurements of the pretherapy proliferative rate of the leukemia cells in vivo, assessment of differentiation in vivo during remission induction therapy, and the level of expression of the fms, myc, and IL1β genes in pretherapy leukemia cells. Short cell cycle times were characteristic of the best prognostic category and were associated with a rapid reduction in marrow leukemia cells in cytosine arabinoside (araC)-sensitive patients. Expression of c-fms was associated with rapid reduction in marrow leukemia cells during araC therapy and with a successful treatment outcome. Expression of the IL1β gene was associated with short remissions. These studies suggest that when compared to newly diagnosed standard prognosis AML, the leukemia of poor prognosis patients is more likely to exhibit long cell cycle times, low levels of fms expression, and is less likely to be associated with myeloid differentiation during remission induction therapy. © 1993 Wiley-Liss, Inc. 相似文献
10.